Screening for Methicillin-Resistant Staphylococcus Aureus (Mrsa)

Screening for Methicillin-Resistant Staphylococcus Aureus (Mrsa) PDF

Author: U. S. Department Human Services

Publisher: Createspace Independent Publishing Platform

Published: 2013-08

Total Pages: 0

ISBN-13: 9781491256442

DOWNLOAD EBOOK →

Methicillin-resistant Staphylococcus aureus (MRSA) emerged as a clinically relevant human pathogen more than five decades ago. The virulent bacterium was first detected in hospitals and other health care facilities where vulnerable hosts, frequent exposure to the selective pressure of intensive antimicrobial therapy, and the necessity for invasive procedures created a favorable environment for dissemination. MRSA emerged as an important cause of healthcare-associated infections, particularly central line-associated bloodstream infection, ventilator-associated pneumonia, and surgical site infection (SSI). Despite the adoption of infection-control measures, the incidence of MRSA infection at most U.S. hospitals steadily increased for many years, but it is now decreasing. While the decrease in the incidence of MRSA infection may be due to efforts to screen for MRSA carriage, it may also be due to secular trends (such as efforts to improve patient safety) and to confounders (such as efforts to improve the appropriate use of antibiotics and to decrease healthcare-associated infections in general, including catheter-associated bloodstream infection, ventilator-associated pneumonia, and SSI). A number of analyses suggest that MRSA infections are associated with increased mortality and cost of care when compared with those due to strains that are susceptible to methicillin. Even the availability of newer pharmaceutical agents with specific activity against MRSA has not ameliorated the challenge of caring for patients with MRSA. The widespread use of these agents has been limited, in part due to toxicity, cost, and uncertainty as to optimal indications. The management and control of MRSA have been further complicated by dramatic changes in the epidemiology of transmission and infection observed over the past two decades. Specifically, S. aureus strains resistant to methicillin, once exclusively linked to hospital care, have increasingly been detected among patients in the community who lack conventional risk factors for MRSA infection. Community-acquired MRSA has been linked to outbreaks of infection in hospitals and health care facilities. Conventional strategies for the control of MRSA have focused on the prevention of spread from patient to patient. The effectiveness of hand hygiene in preventing the spread of MRSA has been demonstrated in observational studies in which hand hygiene promotion campaigns were associated with subsequent reductions in the incidence of MRSA among hospitalized patients. While hand hygiene remains important in the effort to control MRSA transmission, the continued spread of the pathogen after its initial introduction in most facilities has prompted efforts to identify additional strategies. The use of contact isolation-including the donning of gowns and gloves when interacting with patients colonized or infected with MRSA and the assignment of such patients to single rooms or to a room with a group of affected patients-has been widely promoted and adopted. Such isolation precautions now are the centerpiece of most authoritative guidelines for MRSA control. Despite the broad consensus associated with the use of contact isolation for MRSA prevention, the specific evidence in support of this practice remains limited and indirect. The objective of this review was to synthesize comparative studies that examined the benefits or harms of screening for MRSA carriage in the inpatient or outpatient settings. The review examined MRSA-screening strategies applied to all hospitalized or ambulatory patients, as well as screening strategies applied to selected inpatient or outpatient populations, and compared them with no screening or with screening of selected patient populations. The review evaluated MRSA-screening strategies that included screening with or without isolation and with or without attempted eradication/decolonization.

Screening for Methicillin-Resistant Staphylococcus Aureus (Mrsa)

Screening for Methicillin-Resistant Staphylococcus Aureus (Mrsa) PDF

Author: U. S. Department of Health and Human Services

Publisher: CreateSpace

Published: 2013-09-22

Total Pages: 72

ISBN-13: 9781492789642

DOWNLOAD EBOOK →

Methicillin-resistant Staphylococcus aureus (MRSA) emerged as a clinically relevant human pathogen more than 5 decades ago. The virulent bacterium was first detected in hospitals and other health care facilities where vulnerable hosts, frequent exposure to the selective pressure of intensive antimicrobial therapy, and the necessity for invasive procedures created a favorable environment for dissemination. MRSA emerged as an important cause of health care-acquired infections, particularly central line-associated bloodstream infection, ventilator-associated pneumonia, and surgical site infection. Despite the adoption of infection control measures, the incidence of MRSA infection at most hospitals in the U.S. steadily increased for many years, but is now decreasing. Routine clinical cultures may miss a large portion of patients who are silent carriers of these organisms and serve as reservoirs for further transmission. More aggressive measures have been sought to check the spread of this particularly virulent pathogen. Active surveillance screening for MRSA is receiving greater attention for its potential value in identifying carriers of MRSA to prevent further transmission. To identify the population of colonized individuals, microbiological samples are obtained from at-risk patients even in the absence of signs or symptoms of infection. The screening strategy may use a testing modality with a rapid turnaround time. Because screening alone is not expected to affect health outcomes, screening strategies may include screening with or without isolation and with or without attempted decolonization or eradication. A Comparative Effectiveness Review was prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center on Screening for Methicillin-Resistant Staphylococcus aureus (MRSA). The objective of the review was to synthesize comparative studies that examined the benefits or harms of screening for MRSA carriage in the inpatient or outpatient settings. The review examined MRSA-screening strategies applied to all hospitalized or ambulatory patients (universal screening), as well as screening strategies applied to selected inpatient or outpatient populations (e.g., patients admitted to the intensive care unit (ICU), patients admitted for a surgical procedure, or patients at high-risk of MRSA colonization or infection such those on prolonged antibiotic therapy) and compared them to no screening or to screening of selected patient populations (targeted screening). The review evaluated MRSA-screening strategies with or without isolation and with or without attempted eradication/decolonization. The review identified a number of limitations in the evidence that prevents precise estimates of the comparative effectiveness of screening for MRSA-carriage on infection rates, morbidity and mortality. Insufficient numbers of patients were enrolled in studies to be adequately powered to detect the effect of screening for MRSA-carriage compared with no screening or to screening of selected patient populations on morbidity and mortality. Studies failed to take a more uniform approach to the testing strategy used, address test turn-around time, or account for the management of patients before screening test results are known. The existing evidence failed to quantify and account for the potential bias introduced by secular trends that may contribute to variation in the incidence of infectious diseases over time. The evidence failed to account for the influence of concomitant infection prevention strategies and treatment interventions or staff compliance with them. Lacking such a standard, a maximally transparent approach to reporting interventions and potential confounders would be absolutely critical.

Screening for Methicillin-resistant Staphylococcus Aureus (MRSA)

Screening for Methicillin-resistant Staphylococcus Aureus (MRSA) PDF

Author: Susan B. Glick

Publisher:

Published: 2013

Total Pages: 238

ISBN-13:

DOWNLOAD EBOOK →

OBJECTIVES: To synthesize comparative studies that examined the benefits and harms of screening for methicillin-resistant Staphylococcus aureus (MRSA) carriage in the inpatient or outpatient setting. DATA SOURCES: MEDLINE(r), Embase(r), the Cochrane Database of Systematic Reviews, the National Institute for Clinical Excellence, the National Guideline Clearinghouse, and the Health Technology Assessment Programme were searched from January 1990 to March 2012. A search of the gray literature included databases with regulatory information, clinical trial registries, abstracts and conference papers, grants and federally funded research, and information from manufacturers. REVIEW METHODS: We sought studies that compared MRSA screening strategies, including universal screening; screening of selected patient populations (surgery, intensive care unit, high risk); and no screening. Outcomes were MRSA acquisition; MRSA infection; morbidity (including complications of MRSA infection); mortality; adverse events (including allergic and nonallergic toxicity [e.g., hypotension], antimicrobial resistance, reduced quality of care, and medical errors); and hospital resource utilization, such as length of stay. Data were abstracted by a team of reviewers and fact-checked by another team of reviewers. Study quality was assessed using the U.S. Preventive Services Task Force framework. Strength of the body of evidence was assessed according to the Agency for Healthcare Research and Quality "Methods Guide for Effectiveness and Comparative Effectiveness Reviews." RESULTS: Forty-eight studies were abstracted for this review. Of these, only 1 was a randomized controlled trial; the other 47 studies utilized quasi-experimental study designs. Sixteen of the studies attempted to control for confounding and/or secular trends, and therefore had the potential to support causal inferences about the impact of MRSA screening on health outcomes and to contribute to the strength-of-evidence syntheses. This review found low strength of evidence that, compared with no screening, universal screening for MRSA carriage reduces healthcare-associated MRSA infection. For each of the other screening strategies evaluated, this review found insufficient evidence to determine the comparative effectiveness of screening on MRSA acquisition or infection. CONCLUSIONS: There is low strength of evidence that universal screening of hospital patients decreases MRSA infection. However, there is insufficient evidence on other outcomes of universal MRSA screening, including morbidity, mortality, harms, and resource utilization. There is also insufficient evidence to support or refute the effectiveness of MRSA screening on any outcomes in other settings. The available literature consisted mainly of observational studies with insufficient controls for secular trends and confounding to support causal inference, particularly because other interventions were inconsistently bundled together with MRSA screening. Future research on MRSA screening should use design features and analytic strategies addressing secular trends and confounding. Designs should also permit assessment of effects of specific bundles of screening and infection control interventions and address outcomes, including morbidity, mortality, harms, and resource utilization.

Frontiers in Staphylococcus aureus

Frontiers in Staphylococcus aureus PDF

Author: Shymaa Enany

Publisher: BoD – Books on Demand

Published: 2017-03-08

Total Pages: 236

ISBN-13: 9535129813

DOWNLOAD EBOOK →

Staphylococcus was first recognized as a human pathogen in 1880 and was named for its grape cluster-like appearance. In 1884, Staphylococcus aureus was identified and named for its vibrant golden color, which was later found to be the result of golden toxin production. Here, experts examine in-depth patterns of S. aureus colonization and exposures in humans, mammals, and birds that have led to the development of various clinical diseases. The mode of transmission of S. aureus and different methods for its detection in different samples are defined. Conventional antibiotic options to treat this aggressive, multifaceted, and readily adaptable pathogen are becoming limited. Alternative, novel chemotherapeutics to target S. aureus are discussed in the pages within, including herbal medicines, bee products, and modes of delivery.

Bacteriophages: Practical Applications for Nature's Biocontrol

Bacteriophages: Practical Applications for Nature's Biocontrol PDF

Author: Sabah A.A. Jassim

Publisher: Springer

Published: 2017-03-18

Total Pages: 254

ISBN-13: 3319540513

DOWNLOAD EBOOK →

Bacteriophages: Practical Applications for Nature's Biocontrol' presents the latest information on uses in healthcare settings as well as animal husbandry, management and care of farm animals by using enhanced phages to replace antibiotics for growth promotion in animal feed or to prevent, control and treat disease in animals. The book will provide an overview of the function of phages and what researchers need to know, from phage hunting to laboratory design, management, production and application using different tools and methods. These key aspects will be discussed through a series of dedicated chapters, with topics covering auditing, validation, data analysis, microbial identification, culture media, and contamination control, etc.

Screening for Methicillin-resistant Staphylococcus Aureus (MRSA)

Screening for Methicillin-resistant Staphylococcus Aureus (MRSA) PDF

Author: Hussein Z. Noorani

Publisher:

Published: 2013

Total Pages:

ISBN-13:

DOWNLOAD EBOOK →

Methicillin-resistant Staphylococcus aureus (MRSA) emerged as a clinically relevant human pathogen more than 5 decades ago. The virulent bacterium was first detected in hospitals and other health care facilities where vulnerable hosts, frequent exposure to the selective pressure of intensive antimicrobial therapy, and the necessity for invasive procedures created a favorable environment for dissemination. MRSA emerged as an important cause of health care-acquired infections, particularly central line-associated bloodstream infection, ventilator-associated pneumonia, and surgical site infection. Despite the adoption of infection control measures, the incidence of MRSA infection at most hospitals in the United States (U.S.) steadily increased for many years, but is now decreasing. Routine clinical cultures may miss a large portion of patients who are silent carriers of these organisms and serve as reservoirs for further transmission. More aggressive measures have been sought to check the spread of this particularly virulent pathogen. Active surveillance screening for MRSA is receiving greater attention for its potential value in identifying carriers of MRSA to prevent further transmission. To identify the population of colonized individuals, microbiological samples are obtained from at-risk patients even in the absence of signs or symptoms of infection. The screening strategy may use a testing modality with a rapid turnaround time (results available on the same day as the testing is performed, typically using polymerase chain reaction (PCR), intermediate turnaround time (results available next day to 2 days after testing performed) or longer turnaround time (results available greater than 2 days after testing performed, typically culture). Because screening alone is not expected to affect health outcomes, screening strategies may include screening with or without isolation and with or without attempted decolonization or eradication. By detecting the larger population of colonized individuals, at the very least conventional precautions (i.e., hand hygiene and contact isolation) can be implemented in a broader and timelier manner to interrupt horizontal transmission of MRSA. Detection of colonized patients also permits consideration of more aggressive interventions, including attempts at microbiological eradication or decolonization. A Comparative Effectiveness Review (CER) was prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center (BCBSA TEC EPC) on Screening for Methicillin-Resistant Staphylococcus aureus (MRSA). The objective of the CER was to synthesize comparative studies that examined the benefits or harms of screening for MRSA carriage in the inpatient or outpatient settings.1 The review examined MRSA-screening strategies applied to all hospitalized or ambulatory patients (universal screening), as well as screening strategies applied to selected inpatient or outpatient populations (e.g., patients admitted to the intensive care unit (ICU), patients admitted for a surgical procedure, or patients at high-risk of MRSA colonization or infection such those on prolonged antibiotic therapy) and compared them to no screening or to screening of selected patient populations (targeted screening). The review evaluated MRSA-screening strategies with or without isolation and with or without attempted eradication/decolonization.

Antibiofilm Agents

Antibiofilm Agents PDF

Author: Kendra P. Rumbaugh

Publisher: Springer Science & Business Media

Published: 2014-05-08

Total Pages: 495

ISBN-13: 3642538339

DOWNLOAD EBOOK →

This book provides a survey of recent advances in the development of antibiofilm agents for clinical and environmental applications. The fact that microbes exist in structured communities called biofilms has slowly become accepted within the medical community. We now know that over 80% of all infectious diseases are biofilm-related; however, significant challenges still lie in our ability to diagnose and treat these extremely recalcitrant infections. Written by experts from around the globe, this book offers a valuable resource for medical professionals seeking to treat biofilm-related disease, academic and industry researchers interested in drug discovery and instructors who teach courses on microbial pathogenesis and medical microbiology.

Ferri's Clinical Advisor 2021

Ferri's Clinical Advisor 2021 PDF

Author: Fred F. Ferri

Publisher: Elsevier Health Sciences

Published: 2020-06-10

Total Pages: 4158

ISBN-13: 0323713343

DOWNLOAD EBOOK →

Find fast answers to inform your daily diagnosis and treatment decisions! Ferri’s Clinical Advisor 2021 uses the popular "5 books in 1" format to deliver vast amounts of information in a clinically relevant, user-friendly manner. This bestselling reference has been significantly updated to provide you with easy access to answers on 1,000 common medical conditions, including diseases and disorders, differential diagnoses, clinical algorithms, laboratory tests, and clinical practice guidelines—all carefully reviewed by experts in key clinical fields. Extensive algorithms, along with hundreds of new figures and tables, ensure that you stay current with today's medical practice. Contains significant updates throughout, covering all aspects of current diagnosis and treatment. Features 27 all-new topics including chronic rhinosinusitis, subclinical brain infarction, reflux-cough syndrome, radiation pneumonitis, catatonia, end-stage renal disease, and genitourinary syndrome of menopause, among others. Includes new appendices covering common herbs in integrated medicine and herbal activities against pain and chronic diseases; palliative care; and preoperative evaluation. Offers online access to Patient Teaching Guides in both English and Spanish.

Pediatric Osteoarticular Infections

Pediatric Osteoarticular Infections PDF

Author: Anil Agarwal

Publisher: JP Medical Ltd

Published: 2013-01-30

Total Pages: 210

ISBN-13: 9350902893

DOWNLOAD EBOOK →

This concise guide brings orthopaedic surgeons and paediatricians up to date with the latest developments in the management of bone and joint (osteoarticular) infections in children. Beginning with an introduction to the causes and development of osteoarticular disorders, the following chapters discuss their clinical features, laboratory diagnosis and treatment options, both surgical and conservative. Each chapter describes a different infection and its management, with a separate chapter examining drug-resistant osteoarticular tuberculosis and co-infection with HIV. The final section discusses advances and research in the condition. Key points Concise guide to the diagnosis and management of bone and joint infections in children Each chapter discusses a different infection and covers conservative and surgical treatment Final chapter describes new advances and research Includes more than 150 full colour images and illustrations